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Background: The aims of this study were to evaluate the effects of nutritional supplementation with
branched-chain amino acids (BCAA) with zinc component (AminofeelW) on adherence to and outcome of therapy
in patients treated with interferon (IFN) for chronic hepatitis C and cirrhosis and to determine whether to
recommend the supplement.
Methods: In this retrospective study, 51 patients who received IFN therapy were investigated among 203
consecutive patients who visited our hospital and were advised regarding the potential benefit of taking
AminofeelW. Each patient was free to choose whether to purchase and take AminofeelW.
Results: Twenty four patients (group 1-A) took AminofeelW during standard IFN therapy and 13 (group 1-B) did
not. Low-dose, long-term IFN (maintenance) therapy, mainly peglated (Peg)-IFN alpha 2a, was administered to 14
patients who were difficult to treat, because of no effect or harmful side effects with standard IFN therapy, and who
had advanced liver fibrosis. Among the 14, 11 patients (group 2-A) took AminofeelW and 3 (group 2-B) did not. The
prevalence of obesity was significantly higher (P=0.04) in group 1-A than in group 1-B. The rate of adherence to IFN
therapy was higher in group 1-A (83.3%) than in group 1-B (53.8%, P=0.05). There were no significant differences
between the two groups in the rates of sustained virological response (SVR) to IFN therapy. According to
multivariate analysis, two factors, SVR and intake of AminofeelW, were associated with successful adherence to IFN
therapy. The adjusted odds ratios for these two factors were 13.25 and 12.59, respectively, and each was statistically
significant. The SVR rate of maintenance IFN therapy was in 18.2% group 2-A and 0% in group 2-B.
Conclusion: Our data show that BCAA intake is useful for adherence to and effect of IFN therapy for patients with
chronic hepatitis C. Nutritional supplementation with BCAA seems to be useful for HCV-infected patients receiving
IFN therapy because it is impossible to introduce standard treatment for all patients among Japan's aging
population.
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It has been estimated that between 1 and 2 million
Japanese people are chronically infected with hepatitis C
virus (HCV). In Japan, elderly patients are at a higher risk
for hepatocellular carcinoma (HCC) but eradication of
hepatitis C virus (HCV) has a reduced effect on hepato-
carcinogenesis in older patients [1,2]. Therapy using
interferon (IFN), an antiviral agent, reduces the rate of
occurrence of HCC and improves the long-term prognosis
[3,4]. In addition, long-term pegylated (Peg) IFN therapy
reduces the incidence of HCC in patients with hepatitis C
and cirrhosis [5].
The current standard therapy for chronic HCV infection
is a combination of Peg-IFN alpha and ribavirin (RBV).
Although this therapy can achieve a sustained virological
response (SVR) in approximately half of treated indivi-
duals, it is associated with significant gastrointestinal,
hematological, and psychiatric side effects [6-8]. The va-
rious complications of IFN therapy are common reasons
for discontinuation of treatment of HCV [9,10].
Decreases in serum levels of branched-chain amino
acids (BCAA) are often seen in patients with chronic
liver diseases and these decreases lead to a decline in the
production of albumin and detoxification of ammonia.
Therefore, BCAAs are used for the treatment of hypoal-
buminemia and hepatic encephalopathy [11,12]. More
recently, it was reported that BCAA could restore
impaired IFN signaling and inhibit HCV replication
under conditions of malnutrition [13].
BCAA are available as a pharmaceutical agent and
are indicated for "improvement of hypoalbuminemia in
patients with decompensated liver cirrhosis who have
hypoalbuminemia (< 3.5 g/dL) despite adequate dietary
intake". For that reason, in Japan, the health insurance
system is not available for administration of BCAA
agent to patients with hepatitis C and compensated cir-
rhosis who receive IFN treatment. We developed a BCAA
zinc component nutritional supplement (AminofeelW,
Seikatsu Bunkasya Co. Inc. Tokyo, Japan), which is not
a drug, after performing clinical testing on patients
with hepatitis C. On March 1, 2007, Seikatsu Bunkasya
Co released AminofeelW. A dose of AminofeelW con-
tains 5.0 mg zinc and 3200.0 mg BCAA [14]. Our pre-
vious clinical trial in 2006 showed that AminofeelW is a
useful therapeutic nutritional supplement for improve-
ment of insulin resistance, hypoalbuminemia and taste
disorders and showed efficacy and safety in a post-
marketing surveillance study of all HCV-infected
patients [14-17].
This retrospective study was conducted to assess the
value of AminofeelW in IFN therapy for patients with
chronic hepatitis C and cirrhosis. The aim of the analysis
was to determine the therapeutic effects and rate of viral
eradication in patients treated with IFN therapy and todetermine whether to recommend supplementation with
AminofeelW.
Results
Effects of BCAA-enriched supplement and standard IFN
therapy
We compared the characteristics of group 1-A and
group 1-B (Table 1). The prevalence of obesity was sig-
nificantly higher (P=0.04) in group 1-A than group 1-B.
The rate of adherence to IFN therapy was 83.3% (20/24)
in group 1-A patients, and 53.8% (7/13) in group 1-B and
was significantly higher (P=0.05) in group 1-A. The aver-
age total intake AminofeelW in group 1-A was 1,000.0 ±
673.0 g. The most effective of the treatments in group 1-A
and B was combination therapy with Peg-IFN alpha 2b
and RBV. There were no significant differences in the SVR
rates of IFN therapy between the two groups.
Table 2 documents the reasons for discontinuation of
therapy. Adverse events and abnormal laboratory tests
were documented in 6 and 3 patients, respectively. One
patient was lost because of relocation. As adverse events,
encephalopathy, exacerbation of hypothyroidism, fundal
hemorrhage, pneumonia, anorexia, arthralgia, and sleep-
lessness were reported. The abnormal laboratory tests
were elevated transaminases and HCV RNA levels.
Seven of the 10 patients (70%) who discontinued IFN
therapy did not achieve SVR. The HCV genotype of two
patients was 2a, among three patients who achieved
SVR in spite of discontinuing therapy.
Multivariate analysis
All variables in the univariable analyses were included in
multivariable analysis. According to multivariate analysis,
two factors, SVR and intake of AminofeelW, were asso-
ciated with successful completion of IFN therapy. The
adjusted odds ratios for these two factors were 13.25 and
12.59, respectively, and each was statistically significant.
Effects of BCAA-enriched supplement and maintenance
IFN therapy
We compared the characteristics of group 2-A and
group 2-B (Table 3). The SVR rate of long-term IFN
therapy was in 18.2% (2/11) group 2-A patients and 0%
(0/3) in group 1-B. The most useful treatment in group
2-A and B was Peg-IFN alpha 2a monotherapy.
One of two subjects in whom SVR was obtained was a
58-year-old woman who suffered from HCV & hepatitis
B virus (HBV)-related liver cirrhosis. The number of
PLT before IFN therapy was 4.2 × 104/μL. We adminis-
tered IFN beta (3 million units/day for 2 week and
thereafter 3 million units/week) from September 5, 2006,
and changed IFN beta to Peg-IFN alpha 2b and RBV
from February 8, 2007 and to Peg-IFN alpha 2a (45 μg
Table 1 Characteristics of the study population 1 (standard IFN therapy, n=37)





No. subjects n 24 13
Sex male/female 9/15 6/7 NS
Age (mean ± SD), years 62.3 ± 5.5 57.5 ± 12.6 NS
Age range years 50 - 74 26 - 75
IFN therapy for the first
time/retreatment
n 14/10 9/4 NS
Liver diseases CH-C 16 66.7% 11 84.6% NS
CH-C & CH-B 1 4.2% 1 7.7% NS
CH-C & post HCV-related HCC 2 8.3% 0 0.0% NS
LC-C 1 4.2% 0 0.0% NS
LC-C & post HCV-related HCC 4 16.7% 1 7.7% NS
Liver diseases Only CH 17 70.8% 12 92.3% NS
LC or post HCC treatment 7 29.2% 1 7.7% NS
HCV genotype 1b 19 79.2% 9 69.2% NS
2a 3 12.5% 4 30.8% NS
2b 2 8.3% 0 0.0% NS
HCV RNA level High 20 83.3% 11 84.6% NS
Low 4 16.7% 2 15.4% NS
Genotype·HCV RNA level 1b·High 17 70.8% 9 69.2% NS
others 7 29.2% 4 30.8% NS
Extrahepatic manifestations Diabetes millitus (positive %) 8 33.3% 4 30.8% NS
Hypertensiton (positive %) 6 25.0% 2 15.4% NS
Hyperlipidemia (positive %) 2 8.3% 0 0.0% NS
Oral lichen planus (positive %) 0 0.0% 1 7.7% NS
Hyperthyroidism (positive %) 0 0.0% 1 7.7% NS
Hypothyroidism (positive %) 3 12.5% 1 7.7% NS
Total of Aminofeel intake (g) mean ± SD 1000.0 ± 673.0 0 <0.0001
BMI mean ± SD 23.3 ± 3.8 22.0 ± 1.7 NS
Obesity (BMI ≥25 kg/m2) n (%) 7 29.2% 0 0.0% 0.04
RBC (×104/μL) mean ± SD 438.8 ± 45.9 450.2 ± 41.7 NS
Hb (g/dL) mean ± SD 13.7 ± 1.2 14.1 ± 1.5 NS
PLT (×104/μL) mean ± SD 13.3 ± 4.1 15.5 ± 7.0 NS
WBC (μL) mean ± SD 4412.5 ± 1348.9 4853.8 ± 1066.6 NS
PT (%) mean ± SD 86.5 ± 17.9 92.8 ± 6.4 NS
AST (U/I) mean ± SD 59.6 ± 25.9 57.6 ± 36.5 NS
ALT (U/I) mean ± SD 64.7 ± 46.9 73.2 ± 59.2 NS
LDH (U/I) mean ± SD 208.9 ± 42.0 199.5 ± 54.1 NS
gamma GTP (U/I) mean ± SD 38.4 ± 19.5 41.8 ± 33.1 NS
ChE (U/I) mean ± SD 206.4 ± 87.1 262.8 ± 71.1 NS
TP (g/dL) mean ± SD 7.7 ± 0.5 7.6 ± 0.4 NS
Alb (g/dL) mean ± SD 4.00 ± 0.5 4.17 ± 0.2 NS
T.Bil (mg/dL) mean ± SD 1.0 ± 0.3 0.8 ± 0.2 NS
FBS (mg/dL) mean ± SD 117.5 ± 43.7 99.7 ± 14.9 NS
HbA1c (%) mean ± SD 5.4 ± 0.7 5.7 ± 1.0 NS
TC (mg/dL) mean ± SD 167.9 ± 26.6 170.4 ± 13.4 NS
AFP (ng/dL) mean ± SD 8.1 ± 11.5 5.5 ± 3.0 NS
IRI (μU/mL) mean ± SD 31.3 ± 35.6 13.2 ± 7.1 NS
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Table 1 Characteristics of the study population 1 (standard IFN therapy, n=37) (Continued)
HOMA-beta 216.2 ± 11.9 203.8 ± 258.8 NS
HOMA-IR 11.9 ± 21.4 3.3 ± 2.0 NS
Zn (μg/dL) mean ± SD 68.1 ± 11.5 73.9 ± 11.4 NS
Course of IFN
therapy
Peg-IFN alpha 2b/RBV 21 87.5% 8 61.5%
Peg-IFN alpha 2a/RBV 0 0.0% 1 7.7%
Peg-IFN alpha 2a monotherapy 0 0.0% 3 23.1%
Peg-IFN alpha 2a monotherapy -
(change) - Peg-IFN alpha 2a/RBV
0 0.0% 1 7.7%
Peg-IFN alpha 2a monotherapy -
(change) - IFN beta
1 4.2% 0 0.0%
Peg-IFN alpha 2b/RBV - (change) - Peg-IFN
alpha 2a monotherapy - (change) -
Peg-IFN alpha 2b/RBV
1 4.2% 0 0.0%
IFN alpha 1 4.2% 0 0.0%
Continuation of
IFN therapy
Successful continuation 20 83.3% 7 53.8% 0.05
Discontinuation 4 16.7% 6 46.2% 0.05
Effect of IFN
therapy
SVR 12 50.0% 9 69.2% NS
Non-SVR 12 50.0% 4 30.8% NS
HCV, hepatitis C virus; CH-C, chronic hepatitis C; CH-B, chronic hepatitis B; LC-C, liver cirrhosis type C; HCC, hepatocellular carcinoma; RBC, red blood cell; Hb,
hemoglobin; PLT, platelets; WBC, white blood cell; PT, prothrombin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate
dehydrogenase; gamma GTP, gamma-glutamyltransferase; ChE, cholinesterase; TP, total protein; Alb, albumin; T.Bil, total bilirubin; FBS, fasting blood glucose; TC,
total; cholesterol; IRI, immunoreactive insulin; Zn, zinc; SVR, sustained virological response; NS, not significant; IFN, interferon; RBV, ribavirin.




















70 F LC-C & post
HCV-related
HCC
None 1b High Peg-IFN alpha 2b/RBV Encephalopathy Non-SVR
67 F CH-C Hypertenstion,
hyperlipidemia,
and hypothyroidism
1b High Peg-IFN alpha 2b/RBV Exacerbation of
hypothyroidism
Non-SVR
58 F CH-C Diabetes mellitus
and hypertenstion
1b High Peg-IFN alpha 2b/RBV Fundal
hemorrhage
Non-SVR






65 F CH-C None 1b High Peg-IFN alpha 2b/RBV Increased HCV
RNA levels
Non-SVR
26 F CH-C None 2a High Peg-IFN alpha 2b/RBV Relocation SVR
65 F CH-C Hypertenstion 1b High Peg-IFN alpha 2b/RBV Pneumonia Non-SVR
59 F CH-C Hypertenstion 1b High Peg IFN alpha 2a





54 M CH-C Diabetes mellitus 2a Low Peg-IFN alpha 2a
monotherapy
Anorexia SVR
64 M CH-C None 1b High Peg-IFN alpha 2b/RBV Arthralgia and
sleeplessness
SVR
CH-C, chronic hepatitis C; LC-C, liver cirrhosis type C; HCC, hepatocellular carcinoma; SVR, sustained virological response; IFN, interferon; RBV, ribavirin.
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Table 3 Characteristics of the study population 2 (maintenance IFN therapy, n=14)





No. subjects n 11 3
Sex male/female 3/8 3/0 0.02
Age (mean ± SD), years 65.2 ± 5.9 64.3 ± 6.0 NS
Age range years 56 - 73 58 - 70
IFN therapy for the first
time/retreatment
n 5/6 0/3 NS
Liver diseases CH-C 1 9.1% 0 0.0%
CH-C & AIH 1 9.1% 0 0.0%
CH-C & post HCV-related HCC 1 9.1% 1 33.3%
LC-C 5 45.5% 0 0.0%
LC-C & LC-B 1 9.1% 0 0.0%
LC-C & post HCV-related HCC 2 18.2% 2 66.7%
Liver diseases Only CH 2 18.2% 0 0.0% NS
LC or post HCC treatmnet 9 81.8% 3 100.0% NS
HCV genotype 1b 8 72.7% 2 66.7% NS
2a 2 18.2% 0 0.0% NS
unknown 1 9.1% 1 33.3% NS
HCV RNA level High 11 100.0% 3 100.0% NS
Low 0 0.0% 0 0.0% NS
Extrahepatic manifestations Diabetes millitus (positive %) 5 45.5% 1 33.3% NS
Hypertensiton (positive %) 6 54.5% 1 33.3% NS
Hyperlipidemia (positive %) 0 0.0% 0 0.0% NS
Oral lichen planus (positive %) 1 9.1% 0 0.0% NS
Hyperthyroidism (positive %) 2 18.2% 0 0.0% NS
Hypothyroidism (positive %) 1 9.1% 0 0.0% NS
Total of Aminofeel intake (g) mean ± SD 2443.6 ± 3209.3 0 <0.01
BMI mean ± SD 24.3 ± 2.0 24.5 ± 3.1 NS
Obesity (BMI ≥ 25 kg/m2) n (%) 4 36.4% 1 33.3% NS
RBC (×104/μL) mean ± SD 402.3 ± 62.3 417.3 ± 29.5 NS
Hb (g/dL) mean ± SD 13.0 ± 1.5 13.1 ± 1.2 NS
PLT (×104/μL) mean ± SD 9.4 ± 4.8 10.2 ± 4.9 NS
WBC (μL) mean ± SD 3809.1 ± 1045.4 3500.0 ± 1558.8 NS
PT (%) mean ± SD 80.7 ± 22.6 85.3 ± 10.5 NS
AST (U/I) mean ± SD 83.9 ± 44.4 73.7 ± 8.4 NS
ALT (U/I) mean ± SD 77.9 ± 34.9 68.3 ± 6.5 NS
LDH (U/I) mean ± SD 238.7 ± 79.1 211.0 ± 31.2 NS
gamma GTP (U/I) mean ± SD 57.7 ± 35.0 63.0 ± 23.4 NS
ChE (U/I) mean ± SD 166.3 ± 98.4 188.0 ± 42.3 NS
TP (g/dL) mean ± SD 7.4 ± 0.6 7.7 ± 0.6 NS
Alb (g/dL) mean ± SD 3.59 ± 0.5 3.67 ± 0.1 NS
T.Bil (mg/dL) mean ± SD 1.0 ± 0.3 1.1 ± 0.4 NS
FBS (mg/dL) mean ± SD 112.7 ± 18.4 93.3 ± 24.0 NS
HbA1c (%) mean ± SD 5.6 ± 0.8 5.4 ± 0.9 NS
TC (mg/dL) mean ± SD 166.7 ± 20.8 134.5 ± 9.2 NS
AFP (ng/dL) mean ± SD 33.7 ± 70.2 11.7 ± 3.8 NS
IRI (μU/mL) mean ± SD 20.8 ± 15.1 15.6 ± 8.8 NS
HOMA-beta 185.7 ± 184.0 208.6 ± 69.7 NS
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Table 3 Characteristics of the study population 2 (maintenance IFN therapy, n=14) (Continued)
HOMA-IR 6.0 ± 5.3 3.9 ± 3.2 NS
Zn (μg/dL) mean ± SD 62.8 ±10.7 67.0 ± 2.8 NS
Course of IFN therapy Peg-IFN alpha 2a monotherapy 4 36.4% 2 66.7%
Peg-IFN alpha 2a/RBV - (change) -
Peg-IFN alpha 2a monotherapy
4 36.4% 1 33.3%
IFN beta - (change) - Peg-IFN alpha
2b/RBV - (change) - Peg-IFN
alpha 2a monotherapy
1 9.1% 0 0.0%
Peg-IFN alpha 2a monotherapy -
(change) - Peg-IFN alpha 2a/RBV -
(change) - Peg-IFN alpha 2a monotherapy
1 9.1% 0 0.0%
Peg-IFN alpha 2a monotherapy -
(change) - Peg-IFN alpha 2b/RBV
1 9.1% 0 0.0%
Effect of IFN therapy SVR 2 18.2% 0 0.0% NS
Non-SVR 9 81.8% 3 100.0% NS
HCV, hepatitis C virus; CH-C, chronic hepatitis C; LC-C, liver cirrhosis type C; LC-B, chronic hepatitis type B; HCC, hepatocellular carcinoma; AIH, autoimmune
hepatitis; IFN, interferon; RBC, red blood cell; Hb, hemoglobin; PLT, platelets; WBC, white blood cell; PT, prothrombin time; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; LDH, lactate dehydrogenase; gamma GTP, gamma-glutamyltransferase; ChE, cholinesterase; TP, total protein; Alb, albumin; T.Bil, total
bilirubin; FBS, fasting blood glucose; TC, total; cholesterol; IRI, immunoreactive insulin; Zn, zinc; SVR, sustained virological response; NS, not significant; IFN,
interferon; RBV, ribavirin.
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17, 2009.
The other was a 68-year-old woman who suffered
from HCV-related liver cirrhosis and hyperthyroidism.
The number of PLT before IFN therapy was 5.1×104/μL.
We administered her Peg-IFN alpha 2a (90 μg/week)
from July 28, 2004 to July 24, 2009.
Prevalence of extrahepatic manifestations
The prevalence extrahepatic diseases was higher in
group 2 than group 1. The complications in group 1
included: diabetes mellitus (DM) (n=12, 32.4%), hyperten-
sion (n=8, 21.6%), hyperlipidemia (n=2, 5.4%), oral lichen
planus (n=1, 2.7%), hyperthyroidism (n=1, 2.7%), and
hypothyroidism (n=4, 10.8%). The complications in group
2 included: DM (n=6, 42.9%), hypertension (n=7, 50.0%),
oral lichen planus (n=1, 7.1%), hyperthyroidism (n=2,
14.3%), and hypothyroidism (n=1, 7.1%).
Discussion
HCC is one of the most common malignancies, espe-
cially in Japan. The most important risk factors of HCC
are chronic hepatitis C and B and cirrhosis. IFN therapy
has therapeutic benefits but management of therapy is
required because the treatment leads to a number of
side effects [6-10]. The major side effects include fatigue,
influenza-like syndrome, gastrointestinal disturbances
and abnormalities of laboratory tests. The rate of discon-
tinuation of combination therapy with Peg-IFN alfa and
RBV was reported to be 10-26% [6-10]. Most dose dis-
continuations resulted from adverse events, whereas
only a minority required discontinuation due to abnor-
malities of laboratory tests [8]. Fried et al. demonstratedthat a full dosing scheduling of both Peg-IFN and RBV
permits 75% of early virological responders to achieve
SVR, that dose reduction resulted in a fall to 67% and
that discontinuation resulted in a loss of SVR, at
12% [7].
In this study, we showed that intake of a BCAA-
enriched supplement is significantly associated with the
ability to adhere to standard IFN therapy. Our previous
clinical evaluation of the BCAA-enriched supplement,
AminofeelW, in chronic hepatitis C patients who were
not receiving IFN therapy, showed improvement of fa-
tigue, loss of appetite, jitteriness, and leg cramps [14].
Evidence produced elsewhere shows improvement of in-
sulin resistance, hypoalbuminemia, taste disorders, ChE
value, and prothrombin value [14-17]. Kawaguchi et al.
suggested the following three reasons for improvement
of subjective symptoms with BCAA intake: amelioration
of hepatic encephalopathy, improvement of malnourish-
ment by elevated tryptophan levels and increase of
impaired cerebral blood flow [18-21]. Our previous study
using single photon emission computed tomography
(SPECT) showed decreased regional cerebral blood flow
during IFN administration [22]. This phenomenon induces
psychotic symptoms such as a depressive state.
We reported previously a strong association between
hypoalbuminemia and mortality in a hyperendemic area
(X town) of HCV infection in Japan [23]. Residents with
hypoalbuminemia had a mortality of 68.0%; dramatically
higher than the rate of 12.1% among residents who had
normal albumin levels. Improvement of hypoalbuminae-
mia should be considered for improvement of prognosis.
Combination therapy with Peg-IFN and RBV is a use-
ful strategy for patients with hepatitis C but it is
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patients because it is not adapted for abnormal biochem-
ical findings or elderly patients. Liver-protective therapy,
such as oral administration of ursodeoxycholic acid or
intravenous injection of Stronger Neo-minophagen C
(SNMCW), is commonly given to nonresponders to IFN
therapy in Japan [24,25]. SNMCW is a glycyrrhizin pre-
paration that has potent anti-inflammatory activity and
has been used in Japan for centuries to treat allergic
diseases and hepatitis. However, this agent is not con-
sidered to have any antiviral or anticancer effect [26].
We have reported the effect of IFN on alpha-
fetoprotein (AFP) changes in 40 patients with chronic
hepatitis C [27]. AFP was reduced significantly more
in the IFN group than the SNMC group (P = 0.0034).
Therapeutic strategies for hepatitis C, e.g., low-dose
long-term IFN treatment, reduced the incidence not
only of hepatocarcinogenesis but also esophageal varices
during the 17-year observation period [28,29].
There are very few reports that SVR was obtained
by long-term, low dose therapy for chronic hepatitis
C [30]. However, in this study, we succeeded in eradi-
cating HCV from two patients with cirrhosis using
maintenance IFN treatment. HCV is frequently
reported to complicate extrahepatic manifestations
such as oral lichen planus, thyroid disease and DM
[31]. Most of the 10 patients who discontinued stand-
ard IFN therapy had extrahepatic manifestations, and
most of the 14 who received low-dose long-term IFN
therapy also had such manifestations. These manifes-
tations are reported to be exacerbated by IFN therapy
and lead to discontinuation of therapy. These findings
indicate the value of maintenance IFN therapy for
patients with extrahepatic manifestations.
Amongst Japan's aging population, combined therapy
of low-dose long-term IFN and administration of BCAA
is thought to be a treatment to adopt enthusiastically.
BCAA intake seems to be useful for HCV-infected
patients.Conclusion
In conclusion, our data show that BCAA intake is useful
for continuation of IFN therapy for patients with HCV
chronic liver diseases. There is great variability among
subjects with liver disease and, because this is not a ran-
domized study, further investigations are needed.Materials and methods
A total of 203 patients with chronic liver diseases who
had a checkup in Kurume University Hospital from
March 1, 2007 to July 31, 2008 received advice about
the therapeutic effects of, and methods of purchasing,
AminofeelW. Each patient was free to decide whether topurchase and take AminofeelW. We excluded 15 patients
whose uptake rates were below 70%.
Among the remaining 188 patients, there were 51 who
received IFN therapy. Thirty five patients took AminofeelW
and 16 did not. Thirty seven patients received IFN treat-
ment with the aim of eradicating HCV and 14 received
low-dose, long-term (maintenance) IFN treatment aimed
at suppression of hepatocarcinogenesis. Natural IFN alpha,
IFN beta or Peg-IFN alpha 2a was selected for IFN mono-
therapy. Combined standard therapy of Peg-IFN alpha
2b or 2a and RBV was given for 24 to 72 weeks.Group 1 (standard IFN therapy)
Among the 37 patients who received IFN therapy to
eradicate HCV, 24 (group 1-A) took AminofeelW during
therapy and 13 (group 1-B) did not (Table 1). Group 1-A
ranged in age from 50 to 74 years, with an average of
62.3 ± 5.5 years. Group 1-B ranged in age from 26 to
75 years, with an average of 57.5 ± 12.6 years.
The diagnosis of liver disease in group 1-A included:
chronic hepatitis C (n=16), chronic hepatitis C and
hepatitis B (n=1), chronic hepatitis C with post-
treatment of HCC (n=2), HCV-related liver cirrhosis
(n=1), and HCV-related liver cirrhosis with post-
treatment of HCC (n=4). Those of group 1-B included:
chronic hepatitis C (n=11), chronic hepatitis C and
hepatitis B (n=1), and HCV-related liver cirrhosis with
post-treatment of HCC (n = 1).
The end-point was the achievement of the adherence to
IFN and/or RBV therapy, defined as the receipt of ≥ 80%
of scheduled IFN and/or RBV doses for ≥ 80% of the
scheduled treatment period.Group 2 (low-dose, long-term IFN therapy)
Low-dose long-term (maintenance) IFN, usually Peg-
IFN alpha 2a, was administered to 14 patients who were
difficult to treat, because of no effect or harmful side
effects with standard IFN therapy, and who had
advanced liver fibrosis (Table 3). Among the 14, 11
patients (group 2-A) took AminofeelW during therapy
and 3 (group 2-B) did not. Group 2-A ranged in age
from 56 to 73 years, with an average of 65.2 ± 5.9 years.
Group 2-B ranged in age from 58 to 70 years, with an
average of 64.3 ± 6.0 years.
The diagnosis of liver disease in group 2-A included:
chronic hepatitis C (n=1), chronic hepatitis C and auto-
immune hepatitis (n=1), chronic hepatitis C with post-
treatment of HCC (n=1), HCV-related liver cirrhosis
(n=5), HCV and HBV-related liver cirrhosis (n=1), and
HCV-related liver cirrhosis with post-treatment of HCC
(n=2). Those of group 2-B included: chronic hepatitis C
with post-treatment of HCC (n=1), and HCV-related
liver cirrhosis with post-treatment of HCC (n=2).
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All patients were tested for red blood cell (RBC), white
blood cell (WBC), platelets (PLT), hemoglobin (Hb), and
insulin resistance index (IRI), zinc (Zn), fasting blood
glucose (FBS) and HbA1c, and for the following liver
function tests: serum alanine aminotransferase (ALT),
aspartate aminotransferase (AST), lactate dehydrogenase
(LDH), gamma-glutamyltransferase (gamma GTP), cho-
linesterase (ChE), prothrombin time (PT), total bilirubin
(T. Bil), total cholesterol (TC), total protein (TP), and al-
bumin (Alb). The formula for the HOMA-IR is:
HOMA-IR = FBS × fasting insulin/405. The formula for
the HOMA-beta is: HOMA-beta = 360 × fasting insulin/
FBS-63.Evaluation of liver diseases
Anti-HCV was measured using a chemiluminescent en-
zyme immunoassay kit (Lumipulse II HCV, Fujirebio,
Tokyo, Japan). HCV RNA in serum was analyzed by the
Amplicor HCV test (Roche, Tokyo, Japan) up to Decem-
ber 6, 2007 and by quantitative PCR assay (COBAS
AMPLICOR HCV MONITOR v 2.0 Test, COBAS
AmpliPrep/COBAS Taq-Man HCV Test, Roche Molecu-
lar Systems, New Jersey, US) from December 7, 2007
[32,33]. HCV genotype was determined by polymerase
chain reaction assay, using a mixture of primers for the
subtype, as reported previously [34]. HBsAg was assayed
using a chemiluminescent immunoassay kit (Architect,
HBsAg QT, Dainabot, Tokyo, Japan). All patients were
examined using hepatic ultrasonography, computed
tomography, or magnetic resonance imaging in order to
investigate the shape of the liver and lesions occupying
the liver. Liver biopsy was performed on some patients.Evaluation of extrahepatic diseases
IFN therapy may cause or worsen such immunological
diseases or extrahepatic diseases. We examined theses
diseases before IFN therapy. A diagnosis of oral lichen
planus was made on the basis of clinical and/or histo-
pathological features. Obesity was defined as a body
mass index (BMI) ≥ 25 kg/m2. Diagnosis of type 2 DM
was based on the American Diabetic Association (ADA)
criteria of 1997 [35]. Hypertension was defined as a sys-
tolic blood pressure (SBP) of 140 mmHg or higher or a
diastolic blood pressure (DBP) of 90 mmHg or higher,
according to the criteria of JNC-VI of the International
Hypertension Society [36]. Thyroid hormones such as
FT3, FT4 and thyroid stimulating hormone were mea-
sured for all patients and thyroid echography examin-
ation was performed for some patients. Examination of
the upper or lower gastrointestinal tract was performed
on patients for whom it was deemed clinically necessary.Ethical considerations
The retrospective study was approved by the Ethics
Committee of Kurume University on August 4, 2008
(reference number: 06046) in accordance with the
Declaration of Helsinki.
Statistical analysis
All data are expressed as mean ± standard error. Differ-
ences between the two groups were analyzed using the
Mann–Whitney U test, Wilcoxon’s test, and Fisher’s exact
test. Differences were judged significant for p ≤ 0.05 (two-
tailed). P value was rounded off to two decimal places.
Adjusted odds ratios were calculated using logistic regres-
sion analysis. All statistical analyses were conducted using
JMP Version 6 (SAS Institute, Cary, NC, USA). The level
of statistical significance was defined as 0.05.
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